Tags : P-III IMpower130 study

Roche to Present Positive Results of Cancer Immunotherapy Programmes at

Shots: Roche is presenting data that includes results assessing Tecentriq + nab-paclitaxel in Breast Cancer (P-III), Alecensa in lung cancer and Tecentriq in lung (P-III) and liver cancers(P-I) Additionally, presenting Entrectinib’s (RXDX-101) positive results from P-II STARTRK-2, P-I STARTRK-1 and P-I ALKA trials for NTRK gene fusion-positive solid tumors and also received BT and PRIME […]Read More